Literature DB >> 19049546

ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin therapy.

J-K Cha1, H-W Jeon, M-J Kang.   

Abstract

BACKGROUND AND
PURPOSE: Aspirin is an important therapeutic regimen to prevent the recurrent ischemic events or death after acute ischemic stroke. In this study, we evaluated the relationship between the extent of adenosine diphosphate (ADP)-induced platelet aggregation and outcome in acute ischemic stroke patients on aspirin therapy.
METHODS: We selected 107 acute ischemic stroke patients who had been prescribed aspirin and evaluated platelet function test by using optic platelet aggregometer test after 5 days of taking it and investigated the prognosis 90 days after ischemic events. Kaplan-Meyer curve was used for survival analysis.
RESULTS: After stratification of the subjected patients by tertiles of ADP-induced platelet aggregation, the events rates were 7.4%, 9.3% and 30.8% (P = 0.023). In multiple logistic regression analysis, old age over 70 years (OR, 13.7; 95% CI, 2.14-88.07; P = 0.001) and the increased ADP-induced platelet aggregation had independent significance to the risk of primary end-points after acute ischemic stroke (OR, 1.1; 95% CI 1.01 to 1.20; P = 0.026).
CONCLUSIONS: This study showed that the increased ADP-induced platelet aggregation under using aspirin is associated with poor outcome after acute ischemic stroke.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19049546     DOI: 10.1111/j.1468-1331.2008.02306.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  6 in total

1.  High residual platelet reactivity (HRPR) for adenosine diphosphate (ADP) stimuli is a determinant factor for long-term outcomes in acute ischemic stroke with anti-platelet agents: The meaning of HRPR after ADP might be more prominent in large atherosclerotic infarction than other subtypes of AIS.

Authors:  Jae-Kwan Cha; Hyun-Seok Park; Hyun-Wook Nah; Dae-Hyun Kim; Myong-Jin Kang; Jae-Hyung Choi; Jae-Taeck Huh; Hyun-Kyung Suh
Journal:  J Thromb Thrombolysis       Date:  2016-07       Impact factor: 2.300

Review 2.  Antiplatelet resistance in stroke.

Authors:  Mehmet Akif Topçuoglu; Ethem Murat Arsava; Hakan Ay
Journal:  Expert Rev Neurother       Date:  2011-02       Impact factor: 4.618

3.  Indole-3-carbinol improves neurobehavioral symptoms in a cerebral ischemic stroke model.

Authors:  Pankaj Paliwal; Gaurav Chauhan; Deepa Gautam; Debabrata Dash; Shashikant C U Patne; Sairam Krishnamurthy
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-03-30       Impact factor: 3.000

4.  COX-2 Inhibition by Use of Rofecoxib or High Dose Aspirin Enhances ADP-Induced Platelet Aggregation in Fresh Blood.

Authors:  Piet Borgdorff; M Louis Handoko; Yeun Ying Wong; Geert Jan Tangelder
Journal:  Open Cardiovasc Med J       Date:  2010-10-21

5.  Anti-platelet aggregation of Panax notoginseng triol saponins by regulating GP1BA for ischemic stroke therapy.

Authors:  Zhi-Yi Xu; Yang Xu; Xiao-Fang Xie; Yin Tian; Jun-Hui Sui; Yong Sun; Da-Sheng Lin; Xing Gao; Cheng Peng; Yu-Jiang Fan
Journal:  Chin Med       Date:  2021-01-19       Impact factor: 5.455

6.  Dual Therapy with Aspirin and Cilostazol May Improve Platelet Aggregation in Noncardioembolic Stroke Patients: A Pilot Study.

Authors:  Yoichi Ohnuki; Yuko Ohnuki; Saori Kohara; Mie Shimizu; Shunya Takizawa
Journal:  Intern Med       Date:  2017-06-01       Impact factor: 1.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.